Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05314543
Other study ID # 21CH145
Secondary ID 2021-A02341-40
Status Recruiting
Phase N/A
First received
Last updated
Start date November 29, 2021
Est. completion date August 2024

Study information

Verified date April 2024
Source Centre Hospitalier Universitaire de Saint Etienne
Contact Léonard FEASSON, PhD
Phone (0)477120383
Email leonard.feasson@chu-st-etienne.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As part of the preparation at the Paris 2024 Olympic Games, the French rowing and cycling federations and a consortium of researchers met to reach an ultimate goal: to increase the number of medals in these two disciplines for Paris 2024 Olympics.


Description:

The objective of this study is to evaluate the maximum capacity of power production of athletes by describing their power-endurance profile and the physiological factors underlying this maximum power generation capacity. These assessments will guide coaches and athletes for: 1. the best use of athletes' physical abilities (for race strategy, cycling gear ratio or rowing levers) 2. adaptation of training program to improve the maximum capacity of power production of the athletes, in order to increase the number of medals at the Paris Olympics 2024.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - experienced, well-trained (national to international level) rowers and cyclists - written consent Exclusion Criteria: - taking medications interfering with measured parameters - contraindication to competitive sport practice - currently participating in an other structured exercise program - muscular, bone or joint injuries - neurologic disease - pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Hypoxia
Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.

Locations

Country Name City State
France CEPART Le Bourget-du-Lac
France Chu Nantes Nantes
France Chu Saint-Etienne Saint-Étienne

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Saint Etienne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum force produced at zero speed in a fatigue-free condition F0i measurement Month : 3
Primary Speed in a fatigue-free condition V0i measurement Month : 3
Primary Maximum force produced at zero speed at the end of the 3 min. F0e measurement Month : 3
Primary Speed up produced at the end of the 3 min. V0e measurement Month : 3
Secondary Maximal oxygen uptake (VO2max) Cardiac stress test At inclusion
Secondary Maximal Ventilation (VEmax) Cardiac stress test At inclusion
Secondary Cardiac output (QCmax) Cardiac stress test At inclusion
Secondary Maximal cardiac frequency (fcmax) Cardiac stress test At inclusion
Secondary Fibre type determination Muscle biopsy of the vastus lateralis Month : 2
Secondary Microvasculature analysis Muscle biopsy of the vastus lateralis Month : 2
Secondary Muscle enzyme activity (Phosphofructokinase (PFK), lactate dehydrogenase (LDH), citrate synthase (CS) et cyclo-oxygenase (COx)) Muscle biopsy of the vastus lateralis Month : 2
Secondary Maximal voluntary force (N) Comparison before and after exercise Month : 9
Secondary Rate of force development Comparison of force development Month : 9
Secondary Evoked forces (N) Ratio of evoked force at low and high frequencies Month : 9
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1